US2005084498A1PendingUtilityA1

EBV CTL epitopes

Assignee: UNIV MELBOURNE AND THE COMMONWPriority: May 24, 1996Filed: Jan 6, 2004Published: Apr 21, 2005

Est. expiryMay 24, 2016(expired)· nominal 20-yr term from priority

Inventors:Rajiv Khanna Beverley Mavis Kerr Ihor Stephan Misko Denis James Moss Scott Burrows

A61K 39/00C12N 2710/16222Y02A50/30A61K 2039/51C07K 14/005

PatentIndex Score

Cited by

References

Claims

Abstract

The present invention provides cytotoxic Epstein-Barr virus T-cell epitopes. These epitopes are QVKWRMTTL, VFSDGRVAC, VPAPAGPIV, TYSAGIVQI, LLDFVRFMGV, QNGALAINTF, VSSDGRVAC, VSSEGRVAC, VSSDGRVPC, VSSDGLVAC, VSSDGQVAC, VSSDGRVVC, VPAPPVGPIV, VEITPYEPTG, VEITPYEPTW, VELTPYKPTW, RRIYDLIKL, RKIYDLIEL and PYLFWLAGI. The present invention further provides vaccines including one or more of these epitopes, optionally with additional epitopes.

Claims

exact text as granted — not AI-modified

1 - 14 . (canceled)  
     
     
         15 . A peptide consisting of a cytotoxic t-cell epitope consisting essentially of the amino acid sequence QNGALAINTF (SEQ ID NO: 36).  
     
     
         16 . A peptide as claimed in claim  1  consisting of the amino acid sequence QNGALAINTF (SEQ ID NO: 36).  
     
     
         17 . A composition comprising the peptide as claimed in claim  1  in combination with an adjuvant.  
     
     
         18 . The composition of claim  3  wherein the adjuvant is montanide ISA 720.  
     
     
         19 . The composition of claim  3  wherein the adjuvant comprises Quillaia saponins, cholesterol and phospholipids.  
     
     
         20 . A composition comprising the peptide as claimed in claim  2  in combination with an adjuvant.  
     
     
         21 . The composition of claim  6  wherein the adjuvant is montanide ISA 720.  
     
     
         22 . The composition of claim  6 , wherein the adjuvant comprises Quillaia saponins, cholesterol and phospholipids.  
     
     
         23 . The composition of claim  3 , wherein said composition is a water-in-oil emulsion.  
     
     
         24 . The composition of claim  6 , wherein said composition is a water-in-oil emulsion.  
     
     
         25 . A composition comprising the peptide as claimed in claim  1  or  2  in combination with at least one further T-cell epitope.  
     
     
         26 . A composition as claimed in claim  11  wherein the further T-cell epitope is selected from the group consisting of TSLYNLRRGTALLA (SEQ ID NO: 1), DTPLIPLTIF (SEQ ID NO: 2), TVFYNIPPMPL (SEQ ID NO: 3), VEITPYKPTW (SEQ ID NO: 4), VSFIEFVGW [B] (SEQ ID NO: 5), FRKAQIQGL (SEQ ID NO: 6), FLRGRAYGL (SEQ ID NO: 7), QAKWRLQTL (SEQ ID NO:8), SVRDRLARL (SEQ ID NO: 9), YPLHEQHGM (SEQ ID NO: 10), HLAAQGMAY (SEQ ID NO: 11), RPPIFIRRL (SEQ ID NO: 12), RLRAEAGVK (SEQ ID NO: 13), IVTDFSVIK (SEQ ID NO: 14), AVFDRKSDAK (SEQ ID NO: 15), NPTQAPVIQLHAVY (SEQ ID NO: 16), LPGPQVTAVLLHEES (SEQ ID NO: 17), DEPASTEPVHDQLL (SEQ ID NO: 18), RYSIFFDY (SEQ ID NO: 19), AVLLOHEESM (SEQ ID NO: 20), RRARSLSAERY (SEQ ID NO: 21), EENLLDFVRF (SEQ ID NO: 22), KEHVIQNAF (SEQ ID NO: 23), RRIYDLIEL (SEQ ID NO: 24), QPRAPIRPI (SEQ ID NO: 25), EGGVGWRHW (SEQ ID NO: 26), CLGGLLTMV (SEQ ID NO: 27), RRRWRRLTV (SEQ ID NO: 28), RAKFKQLL (SEQ ID NO: 29), RKCCRAKFKQLLQHYR (SEQ ID NO: 30), TYSAGIVQI (SEQ ID NO: 34) and LLDFVRFMGV (SEQ ID NO: 35).  
     
     
         27 . A composition as claimed in claim  11  selected from the group consisting of: (i) a composition comprising the cytotoic T-cell epitopes QNGALAINTF (SEQ ID NO: 36) and LLDFVRFMGV (SEQ ID NO: 35); (ii) a composition comprising the cytotoxic T-cell epitopes QNGALAINTF (SEQ ID NO: 36) and FLRGRAYGL (SEQ ID NO: 7); and (iii) a composition comprising the cytotoxic T-cell epitopes QNGALAINTF (SEQ ID NO: 36) and TYSAGIVQI (SEQ ID NO: 34).  
     
     
         28 . A composition as claimed in claim  11  comprising the cytotoxic T-cell epitopes QNGALAINTF (SEQ ID NO: 36), FLRGRAYGL (SEQ ID NO: 7) AND EENLLDFVRF (SEQ ID NO: 22).  
     
     
         29 . A composition as claimed in claim  11  comprising the cytotoxic T-cell epitopes QNGALAINTF (SEQ ID NO: 36), FLRGRAYGL (SEQ ID NO: 7) AND QPRAPIRPI (SEQ ID NO: 25).  
     
     
         30 . A composition as claimed in claim  11  comprising the cytotoxic T-cell epitopes QNGALAINTF (SEQ ID NO: 36), FLRGRAYGL (SEQ ID NO: 7), EENLLDFVRF (SEQ ID NO: 22) and QPRAPIRPI (SEQ ID NO: 25).  
     
     
         31 . A composition as claimed in claim  11  further comprising at least one antigen against which an anamnestic is elicited.  
     
     
         32 . A composition as claimed in  claim 17  wherein the antigen is selected from the group consisting of tetanus toxoid, a  Bordatella pertussus  antigen, a poliovirus antigen, a purified protein derivative (PPD), and EBV gp350 protein, and helper epitope.  
     
     
         33 . A composition as claimed in cliamed in  claim 17  wherein the antigen is tetanus toxoid.

Join the waitlist — get patent alerts

Track US2005084498A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.